VIÁGO

Viago Bio is a biotechnology company focused on developing next-generation T-cell receptor (TCR) therapies for the treatment of solid tumors. The company utilizes a proprietary discovery platform to identify high-affinity, tumor-specific TCRs that can effectively target and eliminate cancer cells while minimizing off-target effects. By engineering patient T cells with these optimized receptors, Viago Bio aims to overcome the challenges of the immunosuppressive tumor microenvironment. Their approach represents a significant advancement in precision immunotherapy, targeting a broad range of oncogenic drivers across various cancer types.